Literature DB >> 24803164

The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

T Jakobsson1, L-L Vedin2, T Hassan2, N Venteclef3, D Greco4, M D'Amato1, E Treuter1, J-Å Gustafsson5, K R Steffensen2.   

Abstract

We examined the function of the oxysterol receptors (LXRs) in inflammatory bowel disease (IBD) through studying dextran sodium sulfate (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and by elucidating molecular mechanisms underlying their anti-inflammatory action. We observed that Lxr-deficient mice are more susceptible to colitis. Clinical indicators of colitis including weight loss, diarrhea and blood in feces appeared earlier and were more severe in Lxr-deficient mice and particularly LXRβ protected against symptoms of colitis. Addition of an LXR agonist led to faster recovery and increased survival. In contrast, Lxr-deficient mice showed slower recovery and decreased survival. In Lxr-deficient mice, inflammatory cytokines and chemokines were increased together with increased infiltration of immune cells in the colon epithelium. Activation of LXRs strongly suppressed expression of inflammatory mediators including TNFα. While LXRα had anti-inflammatory effects in CD11b(+) immune cell populations, LXRβ in addition had anti-inflammatory effects in colon epithelial cells. Lack of LXRβ also induced CD4(+)/CD3(+) immune cell recruitment to the inflamed colon. Expression of both LXRA and LXRB was significantly suppressed in inflamed colon from subjects with IBD compared with non-inflamed colon. Taken together, our observations suggest that the LXRs could provide interesting targets to reduce the inflammatory responses in IBD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24803164     DOI: 10.1038/mi.2014.31

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  49 in total

1.  Inside the microbial and immune labyrinth: totally gutted.

Authors:  Thomas T Macdonald
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

2.  GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus.

Authors:  Tomas Jakobsson; Nicolas Venteclef; Gudrun Toresson; Anastasios E Damdimopoulos; Anna Ehrlund; Xiaohua Lou; Sabyasachi Sanyal; Knut R Steffensen; Jan-Ake Gustafsson; Eckardt Treuter
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

Review 3.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile.

Authors:  X Hu; K R Steffensen; Z-Y Jiang; P Parini; J-Å Gustafsson; M Gåfvels; G Eggertsen
Journal:  J Intern Med       Date:  2012-03-26       Impact factor: 8.989

5.  Central diabetes insipidus associated with impaired renal aquaporin-1 expression in mice lacking liver X receptor β.

Authors:  Chiara Gabbi; Xiaomu Kong; Hitoshi Suzuki; Hyun-Jin Kim; Min Gao; Xiao Jia; Hideo Ohnishi; Yoichi Ueta; Margaret Warner; Youfei Guan; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-07       Impact factor: 11.205

6.  Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival.

Authors:  Shunya Sasaki; Hiroyuki Yoneyama; Kenji Suzuki; Hidehisa Suriki; Tsuneo Aiba; Shiro Watanabe; Yusuke Kawauchi; Hiroshi Kawachi; Fujio Shimizu; Kouji Matsushima; Hitoshi Asakura; Shosaku Narumi
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

7.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

8.  The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids.

Authors:  Arne Egesten; Mette Eliasson; Anders I Olin; Jonas S Erjefält; Anders Bjartell; Per Sangfelt; Marie Carlson
Journal:  Int J Colorectal Dis       Date:  2007-08-17       Impact factor: 2.571

9.  Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis.

Authors:  Y R Mahida; M Ceska; F Effenberger; L Kurlak; I Lindley; C J Hawkey
Journal:  Clin Sci (Lond)       Date:  1992-03       Impact factor: 6.124

10.  Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Claudia Hindinger; David R Hinton; Stefanie J Kirwin; Roscoe D Atkinson; Margaret E Burnett; Cornelia C Bergmann; Stephen A Stohlman
Journal:  J Neurosci Res       Date:  2006-11-01       Impact factor: 4.164

View more
  15 in total

1.  Electroacupuncture inhibits visceral pain via adenosine receptors in mice with inflammatory bowel disease.

Authors:  Tengfei Hou; Hongchun Xiang; Lingling Yu; Wen Su; Yang Shu; Hongping Li; He Zhu; Lixue Lin; Xuefei Hu; Shangdong Liang; Hong Zhang; Man Li
Journal:  Purinergic Signal       Date:  2019-06-11       Impact factor: 3.765

2.  Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis.

Authors:  Yong Huang; Sushila Dalal; Dionysios Antonopoulos; Nathaniel Hubert; Laura H Raffals; Kyle Dolan; Christopher Weber; Jeannette S Messer; Bana Jabri; Albert Bendelac; A Murat Eren; David T Rubin; Mitch Sogin; Eugene B Chang
Journal:  Inflamm Bowel Dis       Date:  2017-03       Impact factor: 5.325

3.  Differential Role of Liver X Receptor (LXR) α and LXRβ in the Regulation of UDP-Glucuronosyltransferase 1A1 in Humanized UGT1 Mice.

Authors:  Eva Hansmann; Elvira Mennillo; Emiko Yoda; Mélanie Verreault; Olivier Barbier; Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2020-01-24       Impact factor: 3.922

4.  Porphyromonas gingivalis indirectly elicits intestinal inflammation by altering the gut microbiota and disrupting epithelial barrier function through IL9-producing CD4+ T cells.

Authors:  Jiho Sohn; Lu Li; Lixia Zhang; Rajendra P Settem; Kiyonobu Honma; Ashu Sharma; Karen L Falkner; Jan M Novak; Yijun Sun; Keith L Kirkwood
Journal:  Mol Oral Microbiol       Date:  2022-01-07       Impact factor: 4.107

5.  Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.

Authors:  Alessandro Menozzi; Manuel Dall'Aglio; Fausto Quintavalla; Luca Dallavalle; Valentina Meucci; Simone Bertini
Journal:  BMC Vet Res       Date:  2016-10-06       Impact factor: 2.741

6.  Liver X receptor activation promotes differentiation of regulatory T cells.

Authors:  Martin Herold; Johanna Breuer; Stephanie Hucke; Percy Knolle; Nicholas Schwab; Heinz Wiendl; Luisa Klotz
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

7.  Liver X receptors regulate hepatic F4/80 + CD11b+ Kupffer cells/macrophages and innate immune responses in mice.

Authors:  Kaori Endo-Umeda; Hiroyuki Nakashima; Shihoko Komine-Aizawa; Naoki Umeda; Shuhji Seki; Makoto Makishima
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

8.  Molecular and functional heterogeneity of IL-10-producing CD4+ T cells.

Authors:  Leonie Brockmann; Shiwa Soukou; Babett Steglich; Paulo Czarnewski; Lilan Zhao; Sandra Wende; Tanja Bedke; Can Ergen; Carolin Manthey; Theodora Agalioti; Maria Geffken; Oliver Seiz; Sara M Parigi; Chiara Sorini; Jens Geginat; Keishi Fujio; Thomas Jacobs; Thomas Roesch; Jacob R Izbicki; Ansgar W Lohse; Richard A Flavell; Christian Krebs; Jan-Ake Gustafsson; Per Antonson; Maria Grazia Roncarolo; Eduardo J Villablanca; Nicola Gagliani; Samuel Huber
Journal:  Nat Commun       Date:  2018-12-21       Impact factor: 14.919

Review 9.  The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.

Authors:  Michael B Fessler
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

10.  Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases.

Authors:  Shan Yu; Sijia Li; Adam Henke; Evan D Muse; Bo Cheng; Gustav Welzel; Arnab K Chatterjee; Danling Wang; Jason Roland; Christopher K Glass; Matthew Tremblay
Journal:  FASEB J       Date:  2016-03-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.